News

CFF Awards Up to $2M to Advance Eloxx’s Therapy ELX-02

The Cystic Fibrosis Foundation (CFF) is awarding Eloxx Pharmaceuticals up to $2 million in additional funding to support the clinical program of ELX-02, a potential therapy for cystic fibrosis (CF) caused by nonsense mutations. “The Cystic Fibrosis Foundation is committed to accelerating treatments for the underlying cause of…

Cholesterol Metabolism Impaired in CF Mouse Model

The metabolism of cholesterol is impaired in a mouse model of cystic fibrosis, a preliminary study suggests. In the model, there seems to be an altered production of bile salts (those that help with the digestion of fats) that may reduce the digestion and/or absorption of cholesterol. This increases cholesterol’s…